|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG004479572 |
| 003 |
DE-627 |
| 005 |
20230629100626.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2023 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG004479572
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2017-003607-22-DE
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)CCFZ533A2201
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2017-003607-22-SE
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Study of safety and efficacy of CFZ533 in kidney transplant patients
|b A partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability,pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody, CFZ533, in de novo and maintenance kidney transplant recipients (CIRRUS I) - CIRRUS I
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 27-07-2018, Last updated: 2023-06-29
|
| 650 |
|
4 |
|a Medical Condition: Renal transplantation MedDRA version: 20.0Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 2
|
| 650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 21. Juni
|
| 773 |
1 |
8 |
|g year:2023
|g day:21
|g month:06
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003607-22
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 21
|c 06
|
Klinische Studie